 82.6%, DM 28.3%,
CHF 6.5%, COPD 19.6%,
CAD 22%
(C) HTN 87%, DM 32.3%,
CHF 8.4%, COPD 21.2%,
CAD 27.2%

(Continued on next page)

108S.e12

Journal of Vascular Surgery

Hasan et al

January Supplement 2022

Supplementary Table II (online only). Continued.
Author, year
geographic area

Inclusion criteria

Exclusion criteria

Total No. of patients
(A) <2 days (B) 2-14 days (C)
>14 days

Mean
age, years

Male
sex, %

Comorbidities

Azzini et al,6 2016
Italy

Patients with stroke and CAS
who underwent
intravenous therapy and
CEA after intravenous
therapy

NR

(A) 22
(B) 12

(A) 66.5
(B) 68

(A) 82
(B) 67

NR

Barbetta et al,7 2014
Italy

Patients who presented with
an acute onset of a
neurologic deÔ¨Åcit

NR

(A) 25
(B) 27

70

71.1

HTN 83.3, DM 27.7, CAD 30,
PAD 15.5, HLD 53.3,
smoking 62.2

Brandl et al,41 2001
Germany

Patients admitted for CEA

Patients were considered
not eligible for CEA, if they
had an intracerebral
hemorrhage and/or early
signs of territorial infarcts
with disturbance of the
blood-brain barrier were
present

(A) 16
(C) 217

(A) 69.9
(C) NR

(A) 75
(C) NR

NR

Hlvacia et al,10 2017
Switzerland

Consecutive cases with
acute symptomatic
carotid stenosis with ICA
throm